Stocks Comparison
Park Ha Biological Technology vs Meiwu Technology: revenue, profit, margins and growth compared
Park Ha Biological Technology brought in $2.5M of revenue in fiscal 2025, Meiwu Technology $7.1M in fiscal 2025. Revenue changed by +6.0% at Park Ha Biological Technology and +4,368.0% at Meiwu Technology on the year before, so Meiwu Technology grew faster. Park Ha Biological Technology kept -965.0% of its revenue as net profit, Meiwu Technology -262.5%.
Side by side, latest fiscal year
| BYAH | WNW | |
|---|---|---|
| Fiscal year ended | FY2025 (October 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $2.5M | $7.1M |
| Revenue growth | +6.0% | +4,368.0% |
| Net income | -$24.4M | -$18.6M |
| Net margin | -965.0% | -262.5% |
| Free cash flow | -$3K | n/a |
| Free cash flow margin | -0.1% | n/a |
| Earnings per share (diluted) | -$41.38 | -$0.82 |
| Cash | $3.8M | $17.9M |
| Debt | n/a | n/a |
| Price to earnings | n/a | n/a |
| Market value | $6.5M | $66.4M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #923 of 955 · Consumer discretionary | #891 of 955 · Consumer discretionary |
Over the years
Questions about Park Ha Biological Technology and Meiwu Technology
Which is bigger by revenue, Park Ha Biological Technology or Meiwu Technology?
Meiwu Technology is bigger by revenue: $7.1M in fiscal 2025, against $2.5M for Park Ha Biological Technology in fiscal 2025.
Which keeps more of its revenue as profit, Park Ha Biological Technology or Meiwu Technology?
Park Ha Biological Technology had a net margin of -965.0% in fiscal 2025; Meiwu Technology had -262.5% in fiscal 2025.
Which grew revenue faster, Park Ha Biological Technology or Meiwu Technology?
In their latest fiscal years revenue changed by +6.0% at Park Ha Biological Technology and +4,368.0% at Meiwu Technology.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.